Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28651481 | 0.80 | TAAR1 (0.45) | GAAAOC3NPC1RAB9ABCHE | |
| SCHEMBL7867637 | 0.79 | ALDH1A1 (0.55) | ALDH1A1TSHRCA12CA9CA1 | |
| SCHEMBL2688603 | 0.78 | BCHE (0.49) | GAAALDH1A1TSHRPYCR1AOC3 | |
| SCHEMBL516674 | 0.78 | BCHE (0.49) | GAAALDH1A1TSHRPYCR1AOC3 | |
| SCHEMBL4446654 | 0.77 | GAA (0.44) | GAAALDH1A1TSHRCA12CA9 | |
| SCHEMBL11813538 | 0.77 | GAA (0.44) | GAAALDH1A1TSHRCA12CA9 | |
| Hydrochloric Acid SCHEMBL10548138 | 0.77 | BCHE (0.48) | GAAALDH1A1TSHRPYCR1GRIN2D | |
| SCHEMBL4397375 | 0.77 | GAA (0.44) | GAAALDH1A1TSHRCA12CA9 | |
| Hydrochloric Acid SCHEMBL3752186 | 0.77 | BCHE (0.48) | GAAALDH1A1TSHRPYCR1AOC3 | |
| Benzene SCHEMBL10352412 | 0.77 | CYP1A2 (0.33) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001041763-A1 | TREATMENT OF ADDICTION DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2001-06-14 | — | — | WO | claimed |
| US-20080089859-A1 | ADMINISTRATION OF SLEEP RESTORATIVE AGENTS | HOLMAN ANDREW | 2008-04-17 | — | — | US | disclosed |
| EP-1311251-A2 | USE OF DOPAMINE D2/D3 RECEPTOR AGONISTS TO TREAT FIBROMYALGIA | Holman, Andrew J. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020165246-A1 | Administration of sleep restorative agents | HOLMAN ANDREW (US) | 2002-11-07 | — | — | US | disclosed |
| WO-2002069974-A1 | ADMINISTRATION OF SLEEP RESTORATIVE AGENTS | HOLMAN ANDREW (US) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002005797-A2 | USE OF DOPAMINE D2/D3 RECEPTOR AGONISTS TO TREAT FIBROMYALGIA | HOLMAN ANDREW J (US) | 2002-01-24 | — | — | WO | disclosed |
| US-6300365-B1 | ADMINISTERING NON-ERGOT DOPAMINE D.SUB.2 /D.SUB.3 RECEPTOR AGONIST OR ACID ADDITION SALT COMPRISING 3(H)-INDOLONE COMPOUND FOR THERAPY OF FIBROMYALGIA | INMEDIX, LLC | 2001-10-09 | — | — | US | disclosed |
| US-6277875-B1 | FIBROMYALGIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2001-08-21 | — | — | US | disclosed |
| WO-2001041763-A1 | TREATMENT OF ADDICTION DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2001-06-14 | — | — | WO | disclosed |
| EP-0358284-B1 | Derivatized alkanolamines as cardiovascular agents | SCHERING AG (DE) | 1997-08-20 | — | — | EP | disclosed |
| US-5051423-A | Derivatized alkanolamines as cardiovascular agents | SCHERING AG (DE) | 1991-09-24 | — | — | US | disclosed |
| WO-1990000548-A2 | DERIVATIZED ALKANOLAMINES AS CARDIOVASCULAR AGENTS | SCHERING AKTIENGESELLSCHAFT BERLIN AND BERGKAMEN (DE) | 1990-01-25 | — | — | WO | disclosed |
| US-4886812-A | REGULATING DOPAMINE CONCENTRATION; PARKINSON DISEASE, HYPOTENSIVE AGENT, SCHIZOPHRENIA | DR. KARL THOMAE GMBH (DE) | 1989-12-12 | — | — | US | disclosed |
| US-4843086-A | HYPOTENSIVE AGENTS, SCHIZOPHRENIA, PARKINSON'S DISEASE | BOEHRINGER INGELHEIM KG (DE) | 1989-06-27 | — | — | US | disclosed |
| US-4731374-A | PARKINSON*S DISEASE | DR. KARL THOMAE GMBH (DE) | 1988-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165246-A1 | Administration of sleep restorative agents | GAP43, PER2, PSAP | GAA 566/4885ALDH1A1 1071/4885TSHR 4696/4885 |
| US-20080089859-A1 | ADMINISTRATION OF SLEEP RESTORATIVE AGENTS | GAP43, PER2, PSAP | GAA 529/4885ALDH1A1 1002/4885TSHR 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.